Finch Therapeutics Group (NASDAQ:FNCH) versus X4 Pharmaceuticals (NASDAQ:XFOR) Financial Contrast

Finch Therapeutics Group (NASDAQ:FNCHGet Rating) and X4 Pharmaceuticals (NASDAQ:XFORGet Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Volatility and Risk

Finch Therapeutics Group has a beta of -0.7, indicating that its share price is 170% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

20.7% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 33.4% of X4 Pharmaceuticals shares are held by institutional investors. 44.6% of Finch Therapeutics Group shares are held by insiders. Comparatively, 95.9% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Finch Therapeutics Group and X4 Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group 0 0 2 0 3.00
X4 Pharmaceuticals 0 0 3 0 3.00

Finch Therapeutics Group presently has a consensus price target of $17.00, indicating a potential upside of 809.09%. X4 Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 775.58%. Given Finch Therapeutics Group’s higher possible upside, equities research analysts clearly believe Finch Therapeutics Group is more favorable than X4 Pharmaceuticals.

Profitability

This table compares Finch Therapeutics Group and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Finch Therapeutics Group -592.95% -40.10% -34.23%
X4 Pharmaceuticals N/A -175.80% -89.46%

Earnings and Valuation

This table compares Finch Therapeutics Group and X4 Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Finch Therapeutics Group $18.53 million 4.81 -$58.16 million ($1.61) -1.16
X4 Pharmaceuticals $3.00 million 21.17 -$88.70 million ($3.32) -0.28

Finch Therapeutics Group has higher revenue and earnings than X4 Pharmaceuticals. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

X4 Pharmaceuticals beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

About Finch Therapeutics Group

(Get Rating)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

About X4 Pharmaceuticals

(Get Rating)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.